Pennside Partners Welcomes New European Director

7 Top Pharma Trends for 2017

British Pharma Industry Faces Challenges Post-Brexit

Medical 3D Printing Breakthroughs Keep on Coming

Prescription Drugs: To Import or Not to Import?

NHS England Overhauls Access to Cancer Treatments

Pennside Partners Announces Expansion into UK

T-Cell Immunotherapy Market Predicted To Grow

Is 3D Printing The Next Big Thing In Pharma?

Pennside Partners, Ltd. Celebrates 25th Anniversary

Wearable Health Monitors & Apps-Transforming Health Care Delivery

Drug Development Clinical Trial Data – Public or Private?

Is Maine Right About Importing Prescription Drugs?

New Cancer Drugs Fuel Debate over Drug Testing Process

Adherence to Drug Regimens: Implications for Drug Developers

Is NICE Denying Patients the Best Treatments Available Today?

Heads up for the European Cancer Congress in Amsterdam

Do We Need Phase III Randomized Controlled Trials for EVERYTHING?

Defining Success in Clinical Trials: Is Learning Something Enough?

Breakthrough Therapy Opens Door to Streamlined Drug Development

Heads up for ASCO: Our List of Key Oncology Presentations

Pharmaceutical Marketing Cutbacks, Doctors Getting Squeezed

Momentum for Biosimilars is Building. What’s Next?

Molecular Testing in Trouble from Medicare. Who’s on First?

Will Oncology and Pathology Unite on Molecular Testing?

NCI Improvements: Drug Development Opportunity for Pharma and Biotech

Orphan Diseases Open Opportunity for Pharma, Biotech Drug Developers

ASCO GU: Heads-Up for Biotech Drug Development in Kidney Cancer

FDA-Mixed Response to Proposed Faster Drug Development Pathway

FDA to Consider Faster Drug Development via Smaller Clinical Trials

ASCO GI Preview - Heads Up for GI Cancer Drug Development

Breast Cancer Drug Development - Targeting HER2 Activating Mutations

Welcome to Pharma & Biotech Today

Receive Blog Posts by Email

Follow Us

Learn More About Our Services

Learn more about Pennside's pharma war games, strategy workshops, and competitive simulations for the pharma and biotech industries

Learn more about Pennside's pharma launch analog services, including pharma business development, pharma benchmarking, pharma best practices, pharma business analytics, business intelligence, ci, competitive intelligence, pharma launch planning, and other strategic consulting services for the pharmaceutical industry. 

Learn more about Pennside's  pharmaceutical and biotechnology consulting services spanning the following areas: competitive intelligence and monitoring, pipeline analysis and disease landscape consulting, marketing/sales/reimbursement support benchmarking, launch support and best practices benchmarking, customer facing and new commercial models, licensing and support consulting, strategy workshops, and outsourced business intelligence and fixed term contractors consulting for the pharma and biotech industries. 

Learn more about Pennside's Robust Pharma Competitive Intelligence and CI Monitoring Services. We provide superior pharma strategies based on actionable corporate intelligence. 

Learn more about our Oncology Drug Development Support Services: oncology launch analog service, oncology congress coverage service, post-launch intelligence and market monitoring, oncology business development and licensing and M&A support, and tumor/MOA clinical pipeline analysis services. Oncology launch adoption and market strategy services include: launch planning support, primary field intelligence and market insights, oncology competitive pipeline analysis, inlicensing reviews, oncology biomarker analysis, and benchmarking of oncology organizations. Oncology Congress Coverage services include: preparing a targeted congress schedule, attending and capturing key oncology conference information, and presenting oncology conference findings.

Contact Us or Request Information

Experience You Can Trust

Trusted pharma and biotech consulting experts for over 25 years